Albireo pharma, inc. (ALBO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10
Cash flows from operating activities:
Net loss

-62,717

-46,111

-24,414

-

-

-

-

-

-

-

-

Net loss

-

-

-

-16,350

-13,755

-18,737

-14,131

-19,335

-20,747

-10,592

-38,290

Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of liability related to sale of future royalties

8,360

6,975

-

-

-

-

-

-

-

-

-

Accretion of debt discount and amortization of issuance costs

-

-

163

1,065

-

-

-

-

-

-

-

Depreciation and amortization

127

45

35

14

81

197

603

641

725

938

991

Loss on settlement of 2014 Convertible Loans and 2015 Convertible Loans

-

-

-

2,095

-

-

-

-

-

-

-

Gain from the sale of IPR&D

-

-

3,500

-

-

-

-

-

-

-

-

Change in fair value of financial instruments

-

-

251

13

-

-

-

-

-

-

-

Gain on sale of property and equipment

-

14

-

-

-

-

-

-

-

-

-

Gain on sale of property and equipment

-

-

-

-

202

-

-

-

-

-

-

Founder's compensation contributed to capital

-

-

-

-

-

-

-

0

0

0

0

Stock-based compensation expense

7,578

5,546

3,700

1,138

637

868

784

1,538

1,828

4,964

5,628

Unrealized foreign exchange loss

-

-

1,107

-

-

-

-

-

-

-

-

Foreign currency adjustments

-4,006

-4,631

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Trade receivables

-

-

-28

-1,246

-

-

-

-

-

-

-

Stock-based compensation for non-employees

-

-

-

-

-

-

-

0

0

-44

-7

Loss on settlement of debt

-

-

-

-

-

-

-

0

0

0

0

Write-off of capitalized patent expense

-

-

-

-

-

-

-

0

38

0

0

Write-off of loan to related party

-

-

-

-

-

-

-

0

0

0

0

Adjustments to fair value of common stock warrant liability

-

-

-

-

4

1,009

5,107

1,217

-1,510

12,611

-1,254

Prepaid expenses and other current assets

6,331

2,104

467

214

-130

-51

47

-31

-111

41

-117

Other receivables

-

-

339

142

-

-

-

-8

8

-10

11

Other assets

360

-403

245

-183

-

-

-

-

-

-

-

Income taxes receivable

-

-

-

-

-2

-3

-1

-28

-1

-81

-636

Grant receivable

-

-

-

-

-

-

-26

-63

88

0

0

Accounts payable

577

3,171

-

-

-271

249

-74

-39

63

-1,767

982

Trade payables

-

-

263

-1,164

-

-

-

-

-

-

-

Income taxes payable

-

-

-

-

-

-

-75

-26

-2

58

-120

Accrued expenses

-4,095

854

-1,705

3,214

-

-

-703

-247

-128

753

-5,561

Other current and long-term liabilities

-64

-198

273

144

-

-

-

-

-

-

-

Accrued expenses and other liabilities

-

-

-

-

838

175

-

-

-

-

-

Total adjustments

-

-

-

-

1,211

534

-4,592

780

4,050

-7,659

3,909

Net cash provided by (used in) operating activities

-

-

-

-8,784

-12,544

-18,203

-

-

-

-

-

Net cash used in operating activities

-52,919

-26,802

-27,566

-

-

-

-18,723

-18,555

-16,697

-18,251

-34,381

Cash flows from investing activities:
Purchase of property, plant and equipment

540

61

190

3

-

-

49

118

59

189

292

Cash acquired in business combinations

-

-

-

25,483

-

-

-

-

-

-

-

Proceeds from sale of property, plant and equipment

-

14

4,500

-

404

7

-

-

-

-

-

Proceeds from issuance of warrants, net of issuance costs

-

-

-

39

-

-

-

-

-

-

-

Deferred public offering costs

-

-

-

-

-

-

-

0

0

0

0

Stockholder contribution

-

-

-

-

-

-

-

0

0

0

0

Purchase of marketable securities

-

-

-

-

-

-

-

0

0

0

6,000

Sale of marketable securities

-

-

-

-

-

-

-

0

0

6,000

0

Capitalized intellectual properties

-

-

-

-

-

-

-

0

0

0

0

Loan to related party

-

-

-

-

-

-

-

0

0

0

0

Net cash used in investing activities

-540

-47

4,310

-

-

-

-49

-118

-59

5,811

-6,292

Cash flows from financing activities:
Net cash used in investing activities

-

-

-

25,480

404

7

-

-

-

-

-

Warrants exercised

-

-

-

-

-

-

-

0

0

50

0

Net proceeds from employee stock purchase plan

-

-

-

-

-

41

15

30

27

118

325

Net proceeds from ATM facility

-

-

-

-

-

1,591

3,026

-

-

-

-

Net proceeds from equity line

-

-

-

-

-

672

490

-

-

-

-

Net proceeds from sale of unregistered common stock - private placement

-

-

-

-

-

-

-

0

8,587

0

0

Proceeds from issuance of common stock, net of issuance costs

20,775

94,150

48,508

-

-

32,149

0

19,239

0

25,276

8,712

Royalty monetization

-

44,525

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-21

-

-

60

0

90

-150

Proceeds from exercise of options

2,729

507

385

-

-

-

48

75

0

0

68

Payments of principal on borrowings

-

-

3,055

2,157

-

-

-

-

-

-

-

Proceeds from bridge financing

-

-

-

-

-

-

-

0

0

0

0

Net cash provided by financing activities

23,504

139,182

45,838

-

-

-

3,579

19,404

17,105

28,219

8,955

Effect of exchange rate changes on cash and cash equivalents

-2,087

-1,679

718

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-32,042

110,654

23,300

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

7,612

-21

34,453

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

503

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

24,811

-12,161

16,257

-15,193

731

349

15,779

-31,718

Supplemental disclosures of cash and non-cash activities:
Cash paid for income taxes

20

-

-

-

-

-

-

-

-

-

-

Right of use assets and lease obligations recorded upon amended lease agreements

4,747

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

178

-

-

-

0

-

-

-

-

Cash paid for interest

-

-

-

450

-

-

-

0

0

0

0

Settlement of derivative liabilities

-

-

-

2,343

-

-

-

-

-

-

-

Income taxes

-

-

-

-

22

26

25

12

20

0

60

Issuance of restricted stock units to settle bonus accrual

-

-

-

-

-

178

0

-

-

-

-

Conversion of convertible preferred stock to common stock

-

-

-

-

-

-

0

-

-

-

-

Warrants issued in connection with registered direct offering

-

-

-

-

-

-

-

0

0

9,438

2,915

Warrants issued in connection with unregistered common stock private placement

-

-

-

-

-

-

-

0

4,832

0

0

Settlement of debt with Series B preferred stock

-

-

-

-

-

-

-

0

0

0

0

Accrued expenses settled with Series B preferred stock

-

-

-

-

-

-

-

0

0

0

0

Deemed dividend - warrants

-

-

-

-

-

-

-

0

0

0

0

Accretion of fair value of beneficial charge on preferred stock

-

-

-

-

-

-

-

0

0

0

0

Conversion of convertible preferred stock to common stock

-

-

-

-

-

-

-

0

0

0

0

Issuance of restricted stock units to settle accrued bonus

-

-

-

-

-

-

-

0

584

0

0

Kreos Warrants
Shares issued upon cashless exercise of Kreos warrants

-

-

617

-

-

-

-

-

-

-

-